FULGENT GENETICS, INC. Finance Lease, Liability, to be Paid, Year Two
FULGENT GENETICS, INC. (FLGT) had Finance Lease, Liability, to be Paid, Year Two of $366.00 thousand as of 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Notes › Commitment and Contingencies › Finance Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo · last filed 2025-02-28
- 2024-12-31: Finance Lease, Liability, to be Paid, Year Two $366.00K.
- 2024-09-30: Finance Lease, Liability, to be Paid, Year Two $366.00K.
- 2024-06-30: Finance Lease, Liability, to be Paid, Year Two $366.00K.
- 2024-03-31: Finance Lease, Liability, to be Paid, Year Two $366.00K.
| Period end | Finance Lease, Liability, to be Paid, Year Two |
|---|---|
| 2024-12-31 | $366.00K 10-K · filed 2025-02-28 |
| 2024-09-30 | $366.00K 10-Q · filed 2024-11-08 |
| 2024-06-30 | $366.00K 10-Q · filed 2024-08-02 |
| 2024-03-31 | $366.00K 10-Q · filed 2024-05-03 |
| 2023-12-31 | $470.00K 10-K · filed 2024-02-28 |
| 2023-09-30 | $467.00K 10-Q · filed 2023-11-03 |
| 2023-06-30 | $468.00K 10-Q · filed 2023-08-04 |
| 2023-03-31 | $547.00K 10-Q · filed 2023-05-05 |
| 2022-12-31 | $1.03M 10-K · filed 2023-02-28 |
| 2022-09-30 | $1.03M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $818.00K 10-Q · filed 2022-08-04 |
| 2022-03-31 | $376.00K 10-Q · filed 2022-05-05 |
| 2021-12-31 | $383.00K 10-K · filed 2022-02-28 |
| 2021-09-30 | $17.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |